Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. K. C. Pharmaceuticals Inc.
WARNING LETTER
•K. C. Pharmaceuticals Inc.•December 30, 2009

K. C. Pharmaceuticals Inc. – FDA Warning Letter, Dec 30, 2009

Record Details

On May 21, 2010, the FDA issued a Warning Letter to K.C. Pharmaceuticals Inc. following a December 14-30, 2009 inspection of their Pomona, CA facility. The inspection revealed significant violations of Quality System Regulations for Medical Devices (21 CFR Part 820) and Current Good Manufacturing Practice (CGMP) Regulations for Finished Pharmaceuticals (21 CFR Parts 210 and 211), rendering their medical devices and drug products adulterated.

Key violations included: 1. **Inadequate Process Validation (21 CFR § 820.75(a))**: Failed aseptic filling process validations in March and May 2009, with contaminated units, yet lots of Sterile Saline Solution were filled and released between these failures without re-qualification. The firm's response was deemed inadequate for not explaining why products were released before re-qualification and lacking evidence of corrective action implementation. 2. **Insufficient Investigations (21 CFR § 211.192)**: Investigations into media fill failures were inadequate, attributing issues solely to improper aseptic techniques without scientific justification. The firm failed to re-validate filling operations or thoroughly investigate microbial contamination in the water system, which was identified as a source of waterborne microorganisms. The FDA questioned the water system's design and qualification. 3. **Deficient Equipment Design (21

Company
K. C. Pharmaceuticals Inc.
Inspection date
December 30, 2009
Product type
Devices
Office
Los Angeles District Office
Person
  • Alonza E. Cruse (Director)
View Company Profile

ID · 6174fda4-b7c8-48c2-82d2-a0fe0c6a9e5f

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 CFR 82021 CFR 21021 CFR 21121 U.S.C. 351(h)21 CFR 820.75(a)21 CFR 211.19221 CFR 211.6321 CFR 211.42(c)(10)(iv)21 CFR 820.100(a)(2)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore K. C. Pharmaceuticals Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.